Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus

Archives of Internal Medicine

Volumn 165, Issue 12, 2005, Pages 1337-1344

  Plank, Johannes ^a   Siebenhofer, Andrea ^a   Berghold, Andrea ^a   Jeitler, Klaus ^a,c   Horvath, Karl ^a   Mrak, Peter ^b   Pieber, Thomas R ^a,c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b GENERAL HOSPITAL KLAGENFURT   (Austria)

^c JOANNEUM RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ASPART; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN;

CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG EFFECT; DRUG INDUSTRY; EMBASE; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; BLOOD; CHILD; COMPARATIVE STUDY; DIABETES MELLITUS; FEMALE; METABOLISM; MIDDLE AGED; PREGNANCY;

ADOLESCENT; ADULT; CHILD; DIABETES COMPLICATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; PREGNANCY; QUALITY OF LIFE;

EID: 22144484165     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.12.1337     Document Type: Review

References (73)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas and insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKDPS 33). Lancet. 1998;352:837-853.
3. Pieber TR, Brunner GA, Schnedl WJ, Schattenberg S, Kaufmann P, Krejs GJ. Evaluation of a structured outpatient group education program for intensive insulin therapy. Diabetes Care. 1995;18:625-630.
4. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002;325:746-751.
5. Glaser B, Cerasi E. Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. Diabetes Obes Metab. 1999;1:67-74.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
7. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylurea, metformin and insulin therapy in patients with type 2 diabetes: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
8. Heinemann L, Richter B. Clinical pharmacology of human insulin. Diabetes Care. 1993;16(suppl 3):90-100.
9. Zinman B. The physiological replacement of insulin: an elusive goal. N Engl J Med. 1989;321:363-370.
10. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28),Pro(B29)]- human insulin: a rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396-402.
11. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet. 2001;358:739-746.
12. Torlone E, Fanelli C, Rambotti AM, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro (B29)] in IDDM. Diabetologia. 1994;37:713-720.
13. Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Gliksman M. Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis. Clin Ther. 1997;19:656-674.
14. Nielsen FS, Jorgensen LN, Ipsen M, Vooldsgaard AI, Parving HH. Long-term comparison of human insulin analogue A10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia. 1995;38:592-598.
15. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analysis of randomised controlled trials: the QUOROM statement. Lancet. 1999;354:1896-1900.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
17. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
18. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analysis involving cross-over trials: methodological issues. Int J Epidemiol. 2002;31:140-149.
19. Curtin F, Altman DG, Elbourne DR. Meta-analysis combining parallel and cross-over clinical trials, I: continuous outcomes. Stat Med. 2002;21:2131-2144.
20. Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2004;(4):CD003287.
21. Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care. 2001;24:69-72.
22. Hedman CA, Orre-Pettersson AC, Lindstrom T, Arnquist HJ. Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes. Clin Endocrinol (Oxf). 2001;55:107-112.
23. Johansson UB, Adamson UCK, Lins PES, Wredling RAM. Improved blood glucose variability, HBA1c Insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII: the Swedish Multicenter Lispro Insulin Study. Diabetes Metab. 2000;26:192-196.
24. Raskin P, Holcombe JH, Tamborlane WV, et al. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications. 2001;15:295-300.
25. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment: results of a multicenter trial: German Humalog-CSII Study Group. Diabetes Care. 1999;22:784-788.
26. Schmauss S, Konig A, Landgraf R. Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin? Diabet Med. 1998;15:247-249.
27. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes. 1997;46:440-443.
28. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care. 2002;25:439-444.
29. Anderson JH, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment: Multicenter Insulin Lispro Study Group. Diabetes. 1997;46:265-270.
30. Del Sindaco P, Ciofetta M, Lalli C, et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med. 1998;15:592-600.
31. Ferguson SC, Strachan MWJ, Janes JM, Frier BM. Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin. Diabetes Metab Res Rev. 2001;17:285-291.
32. Gale EA. A randomised, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. Diabet Med. 2000;17:209-214.
33. Heller SR. Arniel SA, Mansell P; for the UK Lispro Study Group. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. Diabetes Care. 1999;22:1607-1611.
34. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro: the Benelux-UK Insulin Lispro Study Group. Diabetes Care. 1997;20:1827-1832.
35. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients: UK Insulin Aspart Study Group. Diabetes Care. 1998;21:1904-1999.
36. Home PD, Lindholm A, Riis A. European Insulin Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med. 2000;17:762-770.
37. Iwamoto Y, Akanuma Y, Niimi H, et al. Comparison between insulin aspart and soluble human insulin in type 1 diabetes (IDDM) patients treated with basal-bolus insulin therapy: phase III clinical trial in Japan. J Jpn Diabetes Soc. 2001;44:799-811.
38. Provenzano C, Vero R, Oliva A, et al. Lispro insulin in type 1 diabetic patients on a Mediterranean or normal diet: a randomized, cross-over comparative study with regular insulin. Diabetes Nutr Metab. 2001;14:133-139.
39. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23:583-588.
40. Ciofetta M, Lalli C, Del Sindaco P, et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care. 1999;22:795-800.
41. Annuzzi G, Del Prato S, Arcari R, et al. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. Nutr Metab Cardiovasc Dis. 2001;11:168-175.
42. Recasens M, Aguilera E, Morinigo R, et al. Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving β-cell function at onset of type 1 diabetes mellitus. Diabetes Res Clin Pract. 2003;60:153-159.
43. Jacobs MA, Keulen ET, Kanc K, et al. Metabolic efficacy of preprandial administration of Lys (B28), Pro(B29) human insulin analog in IDDM patients: a comparison with human regular insulin during a three-meal test period. Diabetes Care. 1997;20:1279-1286.
44. Anderson JH, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R; Multicenter Insulin Lispro Study Group. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther. 1997;19:62-72.
45. Vignati L, Anderson JH Jr, Iversen PW; Multicenter Insulin Lispro Study Group. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Clin Ther. 1997;19:1408-1421.
46. Roach P, Trautmann M, Arora V, Sun B, Anderson JH Jr, Haslbeck M. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50. Clin Ther. 1999;21:523-534.
47. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med. 2002;19:393-399.
48. Skrha J, Smahelova A, Andel M, et al. Inzulin lispro zlepsuje postprandialni glykemii u pacientu s diabetes mellitus. Sb Lek. 2002;103:15-21.
49. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:1249-1255.
50. Herz M, Profozic V, Arora V, et al. Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes. Curr Med Res Opin. 2002;18:188-193.
51. Herz M, Arora V, Campaigne BN, Scholtz HE, Potgieter MA, Mollentze W. Humalog Mix 25 improves 24-hour profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. S Afr Med J. 2003;93:219-223.
52. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation: Humalog Mix25 Study Group. Diabetes Care. 1999;22:1258-1261.
53. Ross SA, Zinman B, Campos RV, Strack T. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med. 2001;24:292-298.
54. Holcombe JH, Zalani S, Arora VK, Mast CJ; Lispro in Adolescents Study Group. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther. 2002;24:629-638.
55. Deeb LC, Holcombe JH, Brunelle R, et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics. 2001;108:1175-1179.
56. Tupola S, Komulainen J, Jaaskelainen J, Sipila I. Post-prandial insulin lispro vs. human regular insulin in prepubertal children with type 1 diabetes mellitus. Diabet Med. 2001;18:654-658.
57. Ford-Adams ME, Murphy NP, Moore EJ, et al. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med. 2003;20:656-660.
58. Persson B, Swahn ML, Hjertberg R, et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract. 2002;58:115-121.
59. Jovanovic L, Ilic S, Pettitt DJ, et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care. 1999;22:1422-1427.
60. Mecacci F, Carignani L, Cioni R, et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or insulin lispro: comparison with non-diabetic pregnant women. Eur J Obstet Gynecol Reprod Biol. 2003;111:19-24.
61. Kotsanos JG, Vignati L, Huster L, et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Diabetes Care. 1997;20:948-958.
62. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med. 2003;20:626-634.
63. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med. 1990;7:445-451.
64. Plank J, Wutte A, Brunner G, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care. 2002;25:2053-2057.
65. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro. Diabetes Care. 2003;26:2027-2031.
66. Siebenhofer A, Plank J, Berghold A, et al. Meta-analysis of short acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. Diabetologia. 2004;47:1895-2095.
67. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest. 1985;75:1028-1036.
68. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufrikha M, Guy J. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia. 1993;36:282-291.
69. Jørgensen LN, Didriksen LH, Drejer K. Carcinogen effect of the human insulin analogue B10 Asp in female rats [abstract]. Diabetologia. 1992;35:A3.
70. Kurtzhals P, Schäffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C. Correlation of receptor binding and metabolic and metogenic potencies of insulin analogues designed for clinical use. Diabetes. 2000;49:999-1005.
71. Pramming S, Thorsteinsson B, Bendtson I, Binder C. The relationship between symptomatic and biochemical hypoglycaemia in insulin-dependent diabetic patients. J Intern Med. 1990;228:641-646.
72. DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med. 1991;90:450-459.
73. Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life [letter]? Diabet Med. 1995;12:449-450.